The benefits of the multi-target approach in drug design and discovery

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 4, 2006, Pages 896-897

  Espinoza Fonseca, L Michel ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Alzheimer's disease; Cancer; Drug design; Promiscuous drug

Indexed keywords

ACETYLSALICYLIC ACID; AMINO ACID; FLT3 LIGAND; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ANALGESIA; ARTHRITIS; ARTICLE; CANCER; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; MOLECULAR RECOGNITION; PREECLAMPSIA; THROMBOCYTE AGGREGATION;

EID: 30344479953     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.09.011     Document Type: Editorial

References (6)

1. M.P. Mattson Nature 430 2004 631 639
2. V.C. Stephenson, R.A. Heyding, and D.F. Weaver FEBS Lett. 579 2005 1338 1342
3. B. Ma, M. Shatsky, H.J. Wolfson, and R. Nussinov Protein Sci. 11 2002 184 197
4. M.H. Van Regenmortel J. Mol. Recognit. 12 1999 1 2
5. T. Hampton J. Am. Med. Assoc. (JAMA) 292 2004 419 422
6. M.R. Redimbo Drug Discovery Today 9 2004 431 432